Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Consulting agrmnt
Director departure
Appointed director
CC transcript
Appointed COO
Inv. presentation
IRIDEX CORP (IRIX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended July 1, 2023
08/10/2023 8-K Quarterly results
Docs: "Iridex Reports Second Quarter 2023 Financial Results MOUNTAIN VIEW, Calif., August 10, 2023 -- Iridex Corporation , a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended July 1, 2023."
06/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/15/2023 4 Shuda Scott (Director) has filed a Form 4 on IRIDEX CORP
Txns: Granted 39,267 shares @ $1.91, valued at $75k
06/15/2023 4 LUDLUM KEN (Director) has filed a Form 4 on IRIDEX CORP
Txns: Granted 39,267 shares @ $1.91, valued at $75k
06/15/2023 4 Grove Robert Earle (Director) has filed a Form 4 on IRIDEX CORP
Txns: Granted 39,267 shares @ $1.91, valued at $75k
06/15/2023 4 HUSS BEVERLY A (Director) has filed a Form 4 on IRIDEX CORP
Txns: Granted 39,267 shares @ $1.91, valued at $75k
06/15/2023 4 Devi Nandini (Director) has filed a Form 4 on IRIDEX CORP
Txns: Granted 39,267 shares @ $1.91, valued at $75k
05/24/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/11/2023 10-Q Quarterly Report for the period ended April 1, 2023
05/11/2023 8-K Quarterly results
Docs: "Iridex Reports First Quarter 2023 Financial Results MOUNTAIN VIEW, Calif., May 11, 2023 -- Iridex Corporation , a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended April 1, 2023."
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/09/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Quarterly results
Docs: "Condensed Consolidated Statements of Operations Three Months Ended Twelve Months Ended December 31, January 1, December 31, January 1, 2022 2022 2022 2022 Total revenues $ 15,195 $ 15,254 $ 56,972 $ 53,903 Cost of revenues 8,531 9,252 31,604 31,072 Gross profit 6,664 6,002 25,368 22,831 Operating expenses: Research and development 1,450 2,243 7,175 6,868 Sales and marketing 4,826 4,095 18,178 14,637 General and administrative 1,798 2,061 7,557 8,859 Total operating expenses 8,074 8,399 32,910 30,364 Loss from operations Other income , net 276 60 2,348 Loss from operations before provision for income taxes Provision for income taxes 14 16 65 40 Net loss $ $ $ $ Net loss per share: Basic $ $ $ $ Diluted $ $ $ $ Weighted average shares used in computing net loss per share: Basic 15,990 1..."
01/10/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
11/23/2022 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
11/10/2022 10-Q Quarterly Report for the period ended October 1, 2022
11/10/2022 8-K Quarterly results
Docs: "Iridex Announces Record Third Quarter 2022 Financial Results Company Announces FDA Clearance of new Iridex Pascal® Scanning Laser Platform MOUNTAIN VIEW, Calif., November 10, 2022 -- Iridex Corporation , a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended October 1, 2022."
10/31/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/31/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/03/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/20/2022 SC 13D Roland Brent Alexander reports a 5.5% stake in IRIDEX CORPORATION
08/31/2022 4 Mercer Patrick (COO) has filed a Form 4 on IRIDEX CORP
Txns: Paid exercise price by delivering 71 shares @ $2.55, valued at $181.1
08/15/2022 10-Q Quarterly Report for the period ended July 2, 2022
08/15/2022 8-K Quarterly results
08/01/2022 4 Mercer Patrick (COO) has filed a Form 4 on IRIDEX CORP
Txns: Paid exercise price by delivering 71 shares @ $3.01, valued at $213.7
07/05/2022 4 Mercer Patrick (COO) has filed a Form 4 on IRIDEX CORP
Txns: Paid exercise price by delivering 72 shares @ $2.57, valued at $185
Paid exercise price by delivering 1,728 shares @ $2.57, valued at $4.4k
Paid exercise price by delivering 1,460 shares @ $2.47, valued at $3.6k
Paid exercise price by delivering 2,016 shares @ $2.47, valued at $5k
07/05/2022 4 Bruce David (President and CEO) has filed a Form 4 on IRIDEX CORP
Txns: Paid exercise price by delivering 3,227 shares @ $2.57, valued at $8.3k
Paid exercise price by delivering 5,379 shares @ $2.47, valued at $13.3k
Paid exercise price by delivering 4,640 shares @ $2.47, valued at $11.5k
06/16/2022 4 Shuda Scott (Director) has filed a Form 4 on IRIDEX CORP
Txns: Granted 27,472 shares @ $0
06/16/2022 4 LUDLUM KEN (Director) has filed a Form 4 on IRIDEX CORP
Txns: Granted 27,472 shares @ $0
06/16/2022 4 Grove Robert Earle (Director) has filed a Form 4 on IRIDEX CORP
Txns: Granted 27,472 shares @ $0
06/16/2022 4 HUSS BEVERLY A (Director) has filed a Form 4 on IRIDEX CORP
Txns: Granted 27,472 shares @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy